Brittany Salsman | Meningioma Survivor & ABTA Mentor
Erin Dunbar, MD | Director of Neuro-Oncology, Piedmont Brain Tumor Center
Brittany Salsman | Meningioma Survivor & ABTA Mentor
Erin Dunbar, MD | Director of Neuro-Oncology, Piedmont Brain Tumor Center
Paul McDowell | GBM Survivor & ABTA Mentor

A Future Without Brain Tumors Relies on Your Unwavering Support

The need to accelerate groundbreaking research and expand patient care services has never been greater. Brain tumors remain incredibly difficult to treat due to the blood-brain barrier and its profound resistance to standard treatments. While progress has been made, more must be done.

Robert Johnson
Pituitary Survivor & ABTA Mentor

Melanie Johnson
Caregiver & ABTA Mentor

Katie Groetsema
GBM Survivor & Family

Paul McDowell
GBM Survivor & ABTA Mentor

Tracy Sefcik
Meningioma Survivor

Susan Chang, MD
Neuro-oncologist, Brain Tumor Center, UCSF
Professor, Division of Neuro-Oncology, UCSF

Robert Johnson | Pituitary Survivor & ABTA Mentor

Melanie Johnson | Caregiver & ABTA Mentor

Katie Groetsema | GBM Survivor & Family

Tracy Sefcik | Meningioma Survivor

Susan Chang, MD | Neuro-oncologist, Brain Tumor Center, UCSF
Professor, Division of Neuro-Oncology, UCSF

A Future Without Brain Tumors Relies on Your Unwavering Support

The need to accelerate groundbreaking research and expand patient care services has never been greater. Brain tumors remain incredibly difficult to treat due to the blood-brain barrier and its profound resistance to standard treatments. While progress has been made, more must be done.

The Brain Tumor Community

Needs Your Help

Hear how you can help change lives

Play Video

The Brain Tumor Community Needs Your Help

Hear how you can help change lives

Donate

BRAIN TUMORS ARE RELENTLESS

There is no early detection, no prevention, and few treatment options. And, for brain cancer, there is no cure.

1.1 million children & adults

in the United States are living with a
primary or metastatic brain tumor.

800+ children & adults

are diagnosed with a primary or metastatic brain tumor every single day.

18,000+ adults

will likely die from primary cancerous
brain and CNS tumors this year.

Brain cancer

is the 10th leading cause of cancer death in adults and the #1 cause of cancer death in children.

Only 3 new treatments

for brain tumors have been
discovered in the past 20 years.

We See Hope on the Horizon

Meet Hope Head On is a five-year $50-million campaign that will give us the resources we need to triple our research investment, double the patients we serve, and double federal funding for brain tumor research.

We are determined to meet hope head on.

Ralph DeVitto |
President & CEO, ABTA

Ram Subramanian |
Chair of the Board, ABTA

Imagine a Future Where Not One Life Is Lost to a Brain Tumor

Now, imagine you helped create it

Susan Kramer |
Founder, ABTA

Donate
Imagine a Future Where Not One Life Is Lost to a Brain Tumor

Now, imagine you helped create it

Sabine Schwab |
Anaplastic Astrocytoma Survivor & Advocate

Donate
Imagine a Future Where Not One Life Is Lost to a Brain Tumor

Now, imagine you helped create it

Chad Schafer |
Advocate & Former Caregiver

Donate
Imagine a Future Where Not One Life Is Lost to a Brain Tumor

Now, imagine you helped create it

Susan Kramer | Founder, ABTA

Donate
Imagine a Future Where Not One Life Is Lost to a Brain Tumor

Now, imagine you helped create it

Sabine Schwab | Anaplastic Astrocytoma Survivor & Advocate

Donate
Imagine a Future Where Not One Life Is Lost to a Brain Tumor

Now, imagine you helped create it

Chad Schafer | Advocate & Former Caregiver

Donate

Together, We Can Do This | Our 5-Year Plan

Triple Research Investment

Why: The fastest path to a cure is through science

  • Increase funding to foster early-career researchers to pursue high-risk, high-reward research
  • Establish a flexible fund to support innovative research
  • Invest in large research projects through financial collaboration
  • Enhance the ABTA Alumni Research Network to accelerate scientific exchange
Double Patients Served

Why: To put hope in the hands of all who need it

  • Engage and empower underserved communities
  • Break down barriers to brain tumor education and resources
  • Provide adolescent and young adult education and support
Double Federal Funding

Why: To ensure there’s a patient voice at the center of federal policy initiatives

  • Mobilize advocates to increase awareness and influence federal funding
  • Strengthen partnerships with organizations and federal agencies
  • Impact legislation initiatives
Previous slide
Next slide

To learn more about major gift funding opportunities, contact hope@abta.org.

Help Us Meet Hope Head On

Your support turns hope into action

Five years and $50 million means an extension of life for many patients and an improved quality of life for many patients and their families. It’s just that simple.”

Shawn Hervey-Jumper, MD, Neurosurgeon, Brain Tumor Center, UCSF
Associate Professor, Neurological Surgery, UCSF
~Shawn Hervey-Jumper, MD, Neurosurgeon, Brain Tumor Center, UCSF Associate Professor, Neurological Surgery, UCSF
Help change lives; give now

Help change lives; give now

6Gr2 copy
Help change lives; give now
Progress bar showing $3 Million of $50 Million
Help change lives; give now
Progress bar showing $3 Million of $50 Million
Progress bar showing $3 Million of $50 Million

How your donation matters

Accelerates high-risk, high-impact research; $34 million invested
Seeds generations of innovative researchers who have the potential to transform the understanding and treatment of brain tumors; 700 researchers funded
Provides life-changing emotional and educational assistance for patients and caregivers across all ages and tumor types; 100,000+ supported annually
Helps grow the Patient & Caregiver Mentor Support Program; 995 matches made
Helps influence government funding of all types of brain tumor research
Increases disease awareness, education, and advocacy
Previous slide
Next slide

Accelerates high-risk, high-impact research; $34 million invested

Seeds generations of innovative researchers who have the potential to transform the understanding and treatment of brain tumors; 700 researchers funded

Provides life-changing emotional and educational assistance for patients and caregivers across all ages and tumor types; 100,000+ supported annually

Helps grow the Patient & Caregiver Mentor Support Program; 995 matches made

Helps influence government funding of all types of brain tumor research

Increases disease awareness, education, and advocacy

Make a difference in someone’s life every single day
Donate
Make a difference in someone’s life every single day
Donate
Interested in other ways to help the ABTA? Please download our free toolkit
Thumbnail of Meet Hope Head On Toolkit PDF. How to support the ABTA and promote brain tumor awareness.
Mitchel Berger

Really, the answer comes in research. It’s the research that enables us to better understand this disease, unlock the mysteries behind why the disease forms, how it behaves, and how it could affect the lifespan of an individual.”

Mitchel Berger, MD,
Director, Brain Tumor Center, UCSF
ABTA Board of Directors

Paul McDowell

This is such an essential organization to help people like me, to provide community, to provide answers to scientific questions, to provide comfort, to provide so much of what a brain tumor patient needs.”

Paul McDowell,
GBM Survivor & ABTA Mentor

Ram Subramanian

Through the ABTA CareLine, whether you are newly diagnosed or dealing with a recurrence, you can contact a professional to seek help and support for your needs.”

Ram Subramanian,
Chair of the Board, ABTA

Craig Horbinski, MD, PhD

The ABTA was absolutely pivotal in getting my research career off the ground. And because of them, I was able to grow my research enterprise into a very large group that pursues a lot of meaningful research for a lot of different kinds of cancer.”

Craig Horbinski, MD, PhD,
Director, Neuropathology Division, Northwestern
Director, Northwestern Nervous System Tumor Bank

Melanie Johnson

We need the technology; we need the research; we need a way for patients to get the care quicker than the time it’s taking.”

Melanie Johnson,
Caregiver & ABTA Mentor

Previous slide
Next slide
Mitchel Berger

Really, the answer comes in research. It’s the research that enables us to better understand this disease, unlock the mysteries behind why the disease forms, how it behaves, and how it could affect the lifespan of an individual.”

Mitchel Berger, MD,
Director, Brain Tumor Center, UCSF
ABTA Board of Directors

Paul McDowell

This is such an essential organization to help people like me, to provide community, to provide answers to scientific questions, to provide comfort, to provide so much of what a brain tumor patient needs.”

Paul McDowell,
GBM Survivor & ABTA Mentor

Ram Subramanian

Through the ABTA CareLine, whether you are newly diagnosed or dealing with a recurrence, you can contact a professional to seek help and support for your needs.”

Ram Subramanian,
Chair of the Board, ABTA

Craig Horbinski, MD, PhD

The ABTA was absolutely pivotal in getting my research career off the ground. And because of them, I was able to grow my research enterprise into a very large group that pursues a lot of meaningful research for a lot of different kinds of cancer.”

Craig Horbinski, MD, PhD,
Director, Neuropathology Division, Northwestern
Director, Northwestern Nervous System Tumor Bank

Melanie Johnson

We need the technology; we need the research; we need a way for patients to get the care quicker than the time it’s taking.”

Melanie Johnson,
Caregiver & ABTA Mentor

Previous slide
Next slide

How has a brain tumor touched your life? Whether you’re newly diagnosed, a long-time survivor or a caregiver, we want to hear from you!

Share Your Story

Sign up for our MindMatters e‑newsletter to stay connected.

Subscribe

A Future Without Brain Tumors Relies on Your Unwavering Support

The need to accelerate groundbreaking research and expand patient care services has never been greater. Brain tumors remain incredibly difficult to treat due to the blood-brain barrier and its profound resistance to standard treatments. While progress has been made, more must be done.